T-817MA
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for T-817MA, covering 2013-11-05 to 2023-10-23. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD [Phase 2]